64cu-fbp8
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT03830320)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 64-copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05336695 | Phase 1/Phase 2 (Phase 2) | Mar 29, 2022 | Harvard University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT04022915 | Phase 1 | May 13, 2019 | Harvard University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT03830320 | Phase 1 | Aug 1, 2016 | Harvard University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 3 | 3 | 2 | 2016 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 0 | 2 | 2019 |
2 organizations
Page 1 / 1